KR910016769A - 펩티드 및 그의 용도 - Google Patents

펩티드 및 그의 용도 Download PDF

Info

Publication number
KR910016769A
KR910016769A KR1019910003768A KR910003768A KR910016769A KR 910016769 A KR910016769 A KR 910016769A KR 1019910003768 A KR1019910003768 A KR 1019910003768A KR 910003768 A KR910003768 A KR 910003768A KR 910016769 A KR910016769 A KR 910016769A
Authority
KR
South Korea
Prior art keywords
lys
arg
glu
peptide
seq
Prior art date
Application number
KR1019910003768A
Other languages
English (en)
Other versions
KR930004055B1 (ko
Inventor
데루까쓰 아리마
교오꼬 야마다
다다시 하따나까
도시히꼬 남바
마사오 쓰지
Original Assignee
데루까쓰 아리마
나까무라 히사오
가부시끼가이샤 구라레
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데루까쓰 아리마, 나까무라 히사오, 가부시끼가이샤 구라레 filed Critical 데루까쓰 아리마
Publication of KR910016769A publication Critical patent/KR910016769A/ko
Application granted granted Critical
Publication of KR930004055B1 publication Critical patent/KR930004055B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Abstract

내용 없음

Description

펩티드 및 그의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1에서 얻어진 펩티드를 사용해서 실시예 9에 기재된 방법에 의해 측정한 각 혈청검체의 OD492값 분포도이다, 제2도는 실시예 2에서 얻어진 펩티드를 사용해서 실시예 9에 기재된 방법에 의해 측정한 각 혈청검체의 OD492값 분포도이다, 제3도는 참고예 1에서 얻어진 펩티드를 사용해서 실시예 9에 기재된 방법에 의해 측정한 각 혈청검체의 OD492값 분포도이다.

Claims (13)

  1. Lys Arg Ser Thr Ans(배열번호:2), Arg Arg Tyr Lys Glu Lys Glu Lys(배열번호:4), 또는 Ala Ile Ile Pro Asp Arg GluVal Leu Try(배열번호:6)의 아미노산 배열을 함유하는, 비 A 비 B형 간염 관련 항원에 대해서 특이성을 갖는 항체와 특이적으로 결합하는 능력을 갖는 펩티드.
  2. 제1항에 있어서, 식(1):Lys Asp Arg Thr Gln Glnn Arg Lys Thr Lys Arg Ser Thr Asn Arg Arg Arg Ser Lys Asn Glu LysLys Lys Lys(배열번호:1)로서 나타내는 아미노산 배열을 갖는 펩티드 또는 그의 단편으로 된 펩티드로서, 그 펩티드가Lys Arg Ser Thr Asn(배열번호:2)의 아미노산 배열을 가지며, 비 A 비 B형 간염 관련 항원에 대해서 특이성을 갖는 항체특이적으로 결합하는 능력을 갖는 펩티드.
  3. 제1항에 있어서, 식(2):Glu Lys Lys Gly Glu Ala Ser Asn Gly Glu Ala Glu Asn Asp Thr His Lys Lys Gln Arg Arg Tyr LysGlu Lys Glu Lys Thr Ala Thr Asn Asn Pro Gly Lys Asn Lys Lys Pro Arg(배열번호:4)의 아미노산 배열을 가지며, 비 A 비 B형 간염 관련 항원에 대한 특이성을 갖는 항체와 특이적으로 결합하는 능력을 갖는 펩티드.
  4. 제1항에 있어서, 식(3):Arg Val Val Leu Ser Gly Lys Pro Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp GluMet Glu Glu Cys Ser Gln His Leu Pro Tyr Ile Glu Gln Gly Met Met(배열번호:5)로 나타내는 아미노산 배열을 갖는 펩티드 또는 그의 단편으로 된 펩티드로서, 그 펩티드가 Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr(배열번호:6)의 아미노산배열을 가지며, 비 A 비 B 간염 관련항원에 대한 특이성을 갖는 항체와 특이적으로 결합하는 능력을 갖는 펩티드.
  5. 제2항에 있어서, 식(1):Lys Asp Arg Thr Gln Gln Arg Lys Thr Lys Arg Ser Thr Asn Arg Arg Arg Ser Lys Asn Glu Lys LysLys Lys(배열번호:1)로서 나타내는 펩티드.
  6. 제2항에 있어서, 식(1-a):Thr Lys Arg Ser Thr Asn Arg Arg Arg Ser(배열번호:7)로 나타내는 펩티드.
  7. 제3항에 있어서, 식(2-a):Arg Arg Tyr Lys Glu Lys Glu Lys Thr Ala Thr Asn Asn Pro Gly Lys Asn Lys Lys Pro Arg(배열번호:8)로 나타내는 펩티드.
  8. 제3항에 있어서, 식(2-b):Thr His Lys Lys Gln Arg Arg Tyr Lys Glu Lys Glu Lys(배열번호:9)로 나타내는 펩티드.
  9. 제3항에 있어서, 식(2-c):Arg Arg Tyr Lys Glu Lys Glu Lys Thr Ala(배열번호:10)으로 나타내는 펩티드.
  10. 제4항에 있어서, 식(3-a):Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys Ser Gln HisLeu Pro Tyr Ile Glu Gln Gly Met Met(배열번호:11)로 나타내는 펩티드.
  11. 제4항에 있어서, 식(3-b):Arg Val Val Leu Ser Gly Lys Pro Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr(배열번호:12)로 나타내는 펩티드.
  12. 제4항에 있어서, 식(3-c):Ala Ile Ile Pro Asp Arg Glu Val Leu Tyr(배열번호:13)로 나타내는 펩티드.
  13. 제1~12항중 어느 한항 기재의 펩티드를 함유하는 비 A 비 B형 간염 관련 항원에 특이성을 갖는 항체의 측정시약.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910003768A 1990-03-08 1991-03-08 펩티드 및 그의 용도 KR930004055B1 (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP58700/90 1990-03-08
JP58700 1990-03-08
JP5870090 1990-03-08
JP6743990 1990-03-16
JP67439 1990-03-16
JP67439/90 1990-03-16
JP8010090 1990-03-27
JP80100 1990-03-27
JP80100/90 1990-03-27
JP296899/90 1990-10-31
JP296899 1990-10-31
JP29689990 1990-10-31

Publications (2)

Publication Number Publication Date
KR910016769A true KR910016769A (ko) 1991-11-05
KR930004055B1 KR930004055B1 (ko) 1993-05-19

Family

ID=27463675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910003768A KR930004055B1 (ko) 1990-03-08 1991-03-08 펩티드 및 그의 용도

Country Status (3)

Country Link
US (1) US5247067A (ko)
EP (1) EP0445801A3 (ko)
KR (1) KR930004055B1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA912040B (en) * 1990-03-30 1991-12-24 Akzo Nv Peptides immunochemically reactive with antibodies directed against hepatitis non-a,non-b virus
ES2095852T3 (es) * 1990-12-14 1997-03-01 Innogenetics Nv Antigenos sinteticos para la deteccion de anticuerpos contra el virus de la hepatitis c.
US5910404A (en) 1990-12-14 1999-06-08 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
US6007982A (en) * 1990-12-14 1999-12-28 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
ES2098511T3 (es) 1991-03-26 1997-05-01 Dade Int Inc Procedimiento de diagnosis de hepatitis no-a no-b.
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
ATE364621T1 (de) * 1992-03-06 2007-07-15 Innogenetics Nv Hiv-peptide
DE69334328D1 (de) * 1992-07-16 2010-06-10 Advanced Life Science Inst Inc Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
DE4240980A1 (de) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV Peptidantigene und Verfahren zur Bestimmung von HCV
AU8003894A (en) * 1993-10-29 1995-05-22 Srl Inc. Antigen peptide compound and immunoassay method
CA2566506A1 (en) * 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
CN103620409B (zh) * 2011-05-20 2017-04-12 阿波特日本有限公司 用于减少非特异性结合的免疫检验方法和试剂
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
DK2976325T3 (en) 2013-03-21 2017-06-06 Sanofi Aventis Deutschland SYNTHESIS OF PEPTIDE PRODUCTS CONTAINING CYCLIC IMID
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DE318216T1 (de) * 1987-11-18 1990-06-13 Chiron Corp., Emeryville, Calif., Us Nanbv-diagnostika und vakzine.
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드

Also Published As

Publication number Publication date
EP0445801A3 (en) 1992-07-01
KR930004055B1 (ko) 1993-05-19
EP0445801A2 (en) 1991-09-11
US5247067A (en) 1993-09-21

Similar Documents

Publication Publication Date Title
KR910016769A (ko) 펩티드 및 그의 용도
Michaelsen et al. Primary structure of the" hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit.
Hodges et al. Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin.
Tzartos et al. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit.
Muller et al. Cholecystokinin and its COOH-terminal octapeptide in the pig brain.
Ellerson et al. A fragment corresponding to the CH2 region of immunoglobulin G (IgG) with complement fixing activity
ATE120549T1 (de) Verfahren zur bestimmung von hiv-antikörpern.
Brown et al. Determination of the affinity of antibodies to hepatitis B surface antigen in human sera
WO1992010514A3 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
KR920701246A (ko) 카르복실 말단으로부터 유도된 gm-csf의 길항제
Gomara et al. Use of linear and multiple antigenic peptides in the immunodiagnosis of acute hepatitis A virus infection
Pontzer et al. Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein 1.
Das et al. The main immunogenic region of the nicotinic acetylcholine receptor: interaction of monoclonal antibodies with synthetic peptides
Gall et al. Covalent structure of a human γG-immunoglobulin. X. Intrachain disulfide bonds
FI103975B1 (fi) Immunodiagnostinen nivelreumakoe
KR920703640A (ko) 비a비b형 간염 바이러스 항원 단백질
FI913714A (fi) Peptider med foer a 1-mikroglobulin karakteristiska antigeniska determinanter.
RU2001127439A (ru) Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом
Park et al. Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope
Rhodes et al. The immune response to Epstein-Barr nuclear antigen: conformational and structural features of antibody binding to synthetic peptides
JP2635641B2 (ja) 新規ペプチド類及びその用途
DE19500394C2 (de) Peptide zur Diagnose, zum Nachweis und zur Prävention von Hepatitis C Virus (HCV)-Infektionen
KR940008700A (ko) 사람형 모노클로날 항펩티드 항체 및 이것을 코드하는 dna
KR930004328A (ko) 비-a, 비-b형 펩티드
Lord et al. Functional domains of human interferon gamma probed with antipeptide antibodies

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19960416

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee